IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis

Persistent Link:
http://hdl.handle.net/10150/610179
Title:
IMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesis
Author:
Wang, Yiying; Li, Lingmin; Wang, Yue; Yuan, Zeng; Zhang, Wenjing; Hatch, Kenneth; Zheng, Wenxin
Affiliation:
Department of Obstetrics and Gynecology, Henan Provincial People’s Hospital, Zhengzhou, China; Department of Pathology, University of Arizona College of Medicine, Tucson, AZ; Department of Pathology, Shanxi Medical University, Taiyuan, China; Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, China; Department of Obstetrics and Gynecology, University of Arizona, Tucson, AZ; Arizona Cancer Center, University of Arizona, Tucson, AZ
Issue Date:
2014
Publisher:
BioMed Central
Citation:
Wang et al. Journal of Experimental & Clinical Cancer Research 2014, 33:60 http://www.jeccr.com/content/33/1/60
Journal:
Journal of Experimental & Clinical Cancer Research
Rights:
© 2014 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)
Collection Information:
This item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.
Abstract:
BACKGROUND:Serous tubal intraepithelial carcinoma (STIC) and the p53 signature in tubal mucosa have been supported to be precursor lesions in high-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum. It remains critical to find biomarkers for precursor lesions in order to detect HGSCs efficiently. IMP3 is an oncoprotein that has been explored in human malignancies. No studies have specifically addressed the expression of IMP3 in precursor or early lesions of HGSC. The main purposes of this study are to evaluate if IMP3 plays any role in the process of pelvic serous carcinogenesis by examining its expression in HGSC precursor lesions, to examine the relationship between IMP3 and p53 in those precursor lesions, and to check if IMP3 can be used as a biomarker for early diagnosis.METHODS:Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls. Sections of fallopian tubes with or without STIC , as well as cancers within the ovaries, were studied. IMP3 signature was defined as strong IMP3 cytoplasmic staining in 10 or more consecutive benign-looking tubal epithelial cells. The relationship between IMP3 and p53 overexpression was examined.RESULTS:In the 48 HGSC patients with STIC, IMP3 was positive in 46% of STIC lesions and had a similar positive rate in the invasive components of HGSC. IMP3 was also expressed in normal appearing tubal epithelia (IMP3 signature) in 15 (31%) of 48 HGSC cases with STIC and 10 (16%) of 62 cases without STIC. In contrast, no single IMP3 signature was found in the benign control group. Concordant expression of IMP3 and p53 signatures in the STIC group was found in up to one-third of the cases. There were also five (10%) STIC cases with positive IMP3 and negative p53.CONCLUSIONS:We conclude that IMP3 may be involved in the process and progression of pelvic HGSC and may serve as a complimentary biomarker in diagnosing STIC.
EISSN:
1756-9966
DOI:
10.1186/s13046-014-0060-2
Keywords:
IMP3; Serous tubal intraepithelial carcinoma; STIC; p53 signature; High-grade serous carcinoma
Version:
Final published version
Additional Links:
http://www.jeccr.com/content/33/1/60

Full metadata record

DC FieldValue Language
dc.contributor.authorWang, Yiyingen
dc.contributor.authorLi, Lingminen
dc.contributor.authorWang, Yueen
dc.contributor.authorYuan, Zengen
dc.contributor.authorZhang, Wenjingen
dc.contributor.authorHatch, Kennethen
dc.contributor.authorZheng, Wenxinen
dc.date.accessioned2016-05-20T09:00:25Z-
dc.date.available2016-05-20T09:00:25Z-
dc.date.issued2014en
dc.identifier.citationWang et al. Journal of Experimental & Clinical Cancer Research 2014, 33:60 http://www.jeccr.com/content/33/1/60en
dc.identifier.doi10.1186/s13046-014-0060-2en
dc.identifier.urihttp://hdl.handle.net/10150/610179-
dc.description.abstractBACKGROUND:Serous tubal intraepithelial carcinoma (STIC) and the p53 signature in tubal mucosa have been supported to be precursor lesions in high-grade serous carcinoma (HGSC) of the fallopian tube, ovary, and peritoneum. It remains critical to find biomarkers for precursor lesions in order to detect HGSCs efficiently. IMP3 is an oncoprotein that has been explored in human malignancies. No studies have specifically addressed the expression of IMP3 in precursor or early lesions of HGSC. The main purposes of this study are to evaluate if IMP3 plays any role in the process of pelvic serous carcinogenesis by examining its expression in HGSC precursor lesions, to examine the relationship between IMP3 and p53 in those precursor lesions, and to check if IMP3 can be used as a biomarker for early diagnosis.METHODS:Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls. Sections of fallopian tubes with or without STIC , as well as cancers within the ovaries, were studied. IMP3 signature was defined as strong IMP3 cytoplasmic staining in 10 or more consecutive benign-looking tubal epithelial cells. The relationship between IMP3 and p53 overexpression was examined.RESULTS:In the 48 HGSC patients with STIC, IMP3 was positive in 46% of STIC lesions and had a similar positive rate in the invasive components of HGSC. IMP3 was also expressed in normal appearing tubal epithelia (IMP3 signature) in 15 (31%) of 48 HGSC cases with STIC and 10 (16%) of 62 cases without STIC. In contrast, no single IMP3 signature was found in the benign control group. Concordant expression of IMP3 and p53 signatures in the STIC group was found in up to one-third of the cases. There were also five (10%) STIC cases with positive IMP3 and negative p53.CONCLUSIONS:We conclude that IMP3 may be involved in the process and progression of pelvic HGSC and may serve as a complimentary biomarker in diagnosing STIC.en
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.jeccr.com/content/33/1/60en
dc.rights© 2014 Wang et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0)en
dc.subjectIMP3en
dc.subjectSerous tubal intraepithelial carcinomaen
dc.subjectSTICen
dc.subjectp53 signatureen
dc.subjectHigh-grade serous carcinomaen
dc.titleIMP3 as a cytoplasmic biomarker for early serous tubal carcinogenesisen
dc.typeArticleen
dc.identifier.eissn1756-9966en
dc.contributor.departmentDepartment of Obstetrics and Gynecology, Henan Provincial People’s Hospital, Zhengzhou, Chinaen
dc.contributor.departmentDepartment of Pathology, University of Arizona College of Medicine, Tucson, AZen
dc.contributor.departmentDepartment of Pathology, Shanxi Medical University, Taiyuan, Chinaen
dc.contributor.departmentDepartment of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, Chinaen
dc.contributor.departmentDepartment of Obstetrics and Gynecology, University of Arizona, Tucson, AZen
dc.contributor.departmentArizona Cancer Center, University of Arizona, Tucson, AZen
dc.identifier.journalJournal of Experimental & Clinical Cancer Researchen
dc.description.collectioninformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
All Items in UA Campus Repository are protected by copyright, with all rights reserved, unless otherwise indicated.